Pharma has turned its attention to health equity with razor-sharp focus in recent years. A new wave of strategies are beginning to flood the industry, including better approaches to recruiting diverse populations, attempts to overcome negative perceptions of research and efforts to take trials directly to patient communities.
Included In This Trendline
The FDA pushes concrete plans to further diversity in clinical trials
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist